Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490842 | 0.90 | CYP4F2 (0.34) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL27169981 | 0.90 | CYP4F2 (0.34) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL30182911 | 0.87 | MAPT (0.38) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL16125888 | 0.85 | CYP4F2 (0.39) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL18281904 | 0.85 | GAA (0.41) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL24268653 | 0.85 | MAPT (0.37) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL767404 | 0.85 | CYP4F2 (0.39) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL15744178 | 0.85 | CYP4F2 (0.39) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL29388171 | 0.85 | ALDH1A1 (0.39) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL19255289 | 0.85 | RXRA (0.36) | MAPTRXRARXRBRXRGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731213-A2 | COMBINATION THERAPY INVOLVING MACROCYCLIC INDAZOLE COMPOUNDS | Blossomhill Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024263889-A2 | COMBINATION THERAPY INVOLVING MACROCYCLIC INDAZOLE COMPOUNDS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2023240138-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240140-A1 | INDAZOLE MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| WO-2022271840-A1 | SELECTIVE INDAZOLE LRRK2 INHIBITORS AND METHODS FOR USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271840-A1 | SELECTIVE INDAZOLE LRRK2 INHIBITORS AND METHODS FOR USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-111032656-B | Heterocyclic compound kinase inhibitor and pharmaceutical composition and application thereof | 捷思英达医药技术（上海）有限公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2019037640-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2019-02-28 | — | — | WO | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | MAPT 3793/4885RXRA 4811/4885RXRB 4731/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | MAPT 1252/4885RXRA 925/4885RXRB 684/4885 |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | MAPT 3618/4885RXRA 4266/4885RXRB 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.